Filing Flows › Zevra Therapeutics (ZVRA) › Q2 2026 › vs Q2 2025
Zevra Therapeutics (ZVRA) Q2 2026 vs Q2 2025 (year over year)
Zevra Therapeutics's revenue rose $13.8M (+53%) from $25.9M in Q2 2025 to $39.7M in Q2 2026. Operating margin 42.3% against -274.5% (+316.8 pts).
Zevra Therapeutics, Q2 2026: revenue $39.7M (+53% year over year), operating margin 42.3%, net earnings $8.8M, operating cash flow $17.0M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Operating margin | 42.3% | -274.5% | +316.8 pts |
| Net margin | 22.1% | 288.7% | -266.6 pts |
| Free cash flow margin | 42.4% | -14.7% | +57.1 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $39.7M | $25.9M | $13.8M | +53% |
| Operating profit | $16.8M | −$71.0M | $87.8M | — |
| Costs & expenses | $22.9M | $96.9M | −$74.0M | -76% |
| Pre-tax earnings | $12.8M | $76.9M | −$64.1M | -83% |
| Other expense, net | $4.0M | −$148M | $152M | — |
| Cost of revenue | $1.5M | $12.4M | −$10.9M | -88% |
| Research & development | $4.5M | $3.4M | $1.1M | +31% |
| SG&A | $16.6M | $20.8M | −$4.2M | -20% |
| Other operating costs | $316K | $60.3M | −$60.0M | -99% |
| Net earnings | $8.8M | $74.7M | −$66.0M | -88% |
| Income tax | $4.0M | $2.2M | $1.8M | +84% |
| Depreciation & amortization | $364K | $1.7M | −$1.3M | -78% |
| Share-based compensation | $3.0M | $2.5M | $505K | +20% |
| Working capital & other | $4.9M | −$82.4M | $87.4M | — |
| Operating cash flow | $17.0M | −$3.6M | $20.6M | — |
| Free cash flow (OCF − capex) | $16.8M | −$3.8M | $20.6M | — |
| Capital expenditures | $217K | $213K | $4K | +2% |
Questions
How much did Zevra Therapeutics's revenue grow year over year in Q2 2026?
Zevra Therapeutics's revenue rose $13.8M (+53%) from $25.9M in Q2 2025 to $39.7M in Q2 2026. Operating margin 42.3% against -274.5% (+316.8 pts).